Pulse Biosciences Past Earnings Performance

Past criteria checks 0/6

Pulse Biosciences has been growing earnings at an average annual rate of 1.9%, while the Medical Equipment industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 7.3% per year.

Key information

1.9%

Earnings growth rate

19.8%

EPS growth rate

Medical Equipment Industry Growth4.3%
Revenue growth rate7.3%
Return on equity-58.3%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Pulse Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:6L8 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-461929
30 Jun 240-441729
31 Mar 240-431629
31 Dec 230-421628
30 Sep 230-391424
30 Jun 230-471621
31 Mar 230-512020
31 Dec 221-592621
30 Sep 222-653222
30 Jun 222-613524
31 Mar 222-623426
31 Dec 211-643429
30 Sep 211-623130
30 Jun 210-612931
31 Mar 210-572729
31 Dec 200-502426
30 Sep 200-502426
30 Jun 200-492425
31 Mar 200-492425
31 Dec 190-472325
30 Sep 190-421923
30 Jun 190-411922
31 Mar 190-391920
31 Dec 180-382017
30 Sep 180-372215
30 Jun 180-342113
31 Mar 180-312011
31 Dec 170-261610
30 Sep 170-20118
30 Jun 170-1587
31 Mar 170-1146
31 Dec 160-1036
30 Sep 160-825
30 Jun 160-624
31 Mar 160-423
31 Dec 150-322
30 Sep 150-212

Quality Earnings: 6L8 is currently unprofitable.

Growing Profit Margin: 6L8 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6L8 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare 6L8's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6L8 is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (10.1%).


Return on Equity

High ROE: 6L8 has a negative Return on Equity (-58.3%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 01:48
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Anthony VendettiMaxim Group
Christopher CooleyStephens, Inc.